Global Coalition in Collaboration with Cure Brain Announce
LARKSPUR, Calif.--(BUSINESS WIRE)--Global Coalition for Adaptive Research (GCAR), a 501(c)(3) non-profit research organization, announced that together with their patient/advocacy and pharma/biotech partners, they will ring the Nasdaq Stock Market Closing Bell today to spotlight National Brain Tumor Awareness Month and their innovative, global brain tumor trial called GBM AGILE.
Global Coalition for Adaptive Research, the U.S. Sponsor of REMAP-COVID, announced that Amgen’s apremilast (Otezla) has ended evaluation in the REMAP-COVID study. Apremilast, an oral drug which inhibits the activity of PDE4 (Phosphodiesterase 4), was selected for evaluation because it was hypothesized to inhibit the inflammatory response associated with the signs, symptoms and pulmonary involvements observed in some COVID-19 patients by modulating the production of inflammatory cytokines.